Technology Innovation Institute’s Directed Energy Research Center to Host GLOBALEM Conference in Abu Dhabi in November 2022
5.7.2022 12:14:00 EEST | Business Wire | Press release
The Technology Innovation Institute (TII), a leading global research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) today announced that its Directed Energy Research Center (DERC), will organize the upcoming edition of GLOBALEM, a definitive high power electromagnetic (HPEM) conference.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005033/en/
Technology Innovation Institute’s Directed Energy Research Center to Host GLOBALEM Conference in Abu Dhabi in November 2022 (photo: AETOSWire)
Set to run from November 13 to 17 at St. Regis Abu Dhabi, the conference marks the first high-profile event DERC is hosting after the launch of its prequalification testing facility at Tawazun Industrial Park in Abu Dhabi dedicated to a specific high-energy physics domain.
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Center, will offer expertise as General Chair of the organizing committee of GLOBALEM. Other expert members include Dr. Bill Radasky, of Metatech Corporation USA, and Dr. Nicolas Mora from DERC as joint Technical Program Committee co-chairs, as well as Dr. Felix Vega from DERC, Dr. Lars Ole Fichte from the Helmut-Schmidt University in Hamburg, Germany, and Dr. Jane Lehr, from the University of New Mexico, USA, as conference advisors.
Unpacking the challenges and opportunities that currently exist as well as those evolving everyday in the crucial field of electromagnetics, the conference is set to draw the interest of experts from fields as diverse as pulsed power technologies, high voltage generator, microwaveradiation, covering analytical and numerical modeling as well as experimental validation
All eyes will be trained on the Best Student Paper Award (BSPA), with award recipients receiving a certificate and a cash prize of US$500.
Likewise, the Young Scientist Award (YSA) recognizes a young researcher under 35 who has made innovative contributions in fields related to HPEM. Researchers keen to participate in the contest can nominate themselves during the submission process.
For both awards, the last date for the submission of extended abstracts online is July 1, 2022. Acceptance confirmations and nominations will be completed by August 15, and September 15 is the last date for the final review and submission of full papers and award nominations. Early bird registration is open until September 30, 2022.
Highlighting the significance of the conference for the TII ecosystem and for Abu Dhabi as well, Dr. Kasmi said: “The GLOBALEM conference promises to be a game changer for the region. High Power Electromagnetics is one of those hot areas in focus today for us at DERC, given the varied number of applications and sectors it straddles – from your everyday generators, motors, and transformers, to maglev trains, and astronomy to health care and everything in between. We are even focusing on new innovations that can treat certain types of cancer. Being able to convene so many global experts in Abu Dhabi is unprecedented and is a big deal for TII and the region.”
For more information on the GLOBALEM Conference 2022, and to submit scientific papers please visit: https://globalem2022.com/submission.php
About the Technology Innovation Institute (TII)
The Technology Innovation Institute (TII) is the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), and a leading global scientific research center that focuses on shaping breakthrough solutions and new-age technology capabilities. In working with exceptional talent, universities, research institutions and industry partners from around the world, TII connects an intellectual community and contributes to building a thriving R&D ecosystem that elevates the status of Abu Dhabi and the UAE as a global hub for innovation. For more information, please visit www.tii.ae
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005033/en/
Contact information
Technology Innovation Institute
Sneha Sivanand, sneha.sivanand@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom